Juergen K. Willmann, M.D.
Academic Appointments
- Associate Professor, Radiology - Diagnostic Radiology
- Member, Bio-X
Key Documents
Contact Information
-
Clinical Offices
Department of Radiology 300 Pasteur Dr H1307 MC 5621 Stanford, CA 94305 Tel Work (650) 725-1812 Fax (650) 723-1909
- Academic Offices
Personal Information EmailAdministrative Contact Jocelyn Steffen Administrative Associate Email Tel Work 650-725-1812Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- Diagnostic Radiology
- Abdominal and Pelvic Imaging
Administrative Appointments
- Section Chief, Abdominal Imaging, Department of Radiology Stanford University Medical Center, Stanford University Hospital (2013 - present)
- Associate Chief, Abdominal Imaging, Department of Radiology Stanford University Medical Center, Stanford University Hospital (2012 - 2013)
- Member BioX, Stanford University (2012 - present)
- Member, Stanford Cancer Center (2009 - present)
- Principal Investigator, Translational Molecular Imaging Laboratory (TMIL) (2008 - present)
- Member, Center for Biomedical Imaging at Stanford (CBIS) (2008 - present)
Honors and Awards
- Tenure, Stanford University (2011)
- 2011 Roscoe E. Miller Award of the Society of Gastrointestinal Radiology, USA, Society of Gastrointestinal Radiology (2011)
- 2010 Roscoe E. Miller Award of the Society of Gastrointestinal Radiology, USA, Society of Gastrointestinal Radiology (2010)
- 2010 Radiology Editor's Recognition Award with Distinction as an outstanding reviewer, Radiological Society of North America (2010)
- The Walter Friedrich Award for Outstanding Research in Radiology, German Society of Radiology (2009)
- Molecular Pathogenesis of Digestive Diseases, Pilot Award, Digestive Disease Center Pilot Feasability Program (2009)
Professional Education
| Residency: | University Hospital Zurich, Switzerland (2003) |
| Internship: | University Hospital Freiburg, Germany (1999) |
| Medical Education: | Albert-Ludwigs-University Freiburg, Germany (1998) |
Postdoctoral Advisees
Sunitha Bachawal, Steven Machtaler, Huaijun Wang, Tzu Yin Wang, Katheryne Wilson
Graduate & Fellowship Program Affiliations
Internet Links
Industry Relationships
Stanford is committed to ethical and transparent interactions with our industrial and other commercial partners. It is our policy to disclose payments (exclusive of travel support) from, and/or equity in, companies or other commercial entities to Stanford faculty of $5,000 or more in total value, as well as any equity in a privately held company, when the faculty member also has institutional responsibilities related to his or her interactions with the company. View Full Information
Scientific Focus
Current Research Interests
In the United States, cancer continues to be the leading cause of death in patients between 25 and 64 years of age, and the second leading cause of death in patients both above 65 years and between 1 and 14 years. Since prognosis and survival of patients with cancer highly depend on the tumor stage at the time of diagnosis, early cancer detection shows great promise in prolonging survival and improving quality of life in cancer patients. Therefore, novel imaging strategies are highly desirable that allow detection of cancer at early, still curable stages. Furthermore, with the advent of novel therapeutic options for cancer patients there is an increasing demand for non-invasive imaging biomarkers to identify those patients early on that benefit most from a given treatment or to terminate or modify treatment for those patients not responding to a certain treatment.
In my laboratory we focus on the development and clinical translation of novel molecular and functional imaging biomarkers with special focus on imaging abdominal and pelvic cancer including pancreatic, liver, renal, ovarian, and prostate cancer. We further advance clinically available radiological imaging modalities such as ultrasound, magnetic resonance imaging (MRI), and positron emission tomography (PET) as promising imaging tools for early detection and treatment monitoring of abdominal and pelvic cancer. Our mission is to integrate novel molecular and functional imaging strategies into clinical protocols for improved patient care in the near future.
Clinical Trials
- Recruiting 3D Dynamic Contrast-Enhanced Ultrasound Imaging in Predicting Treatment Response in Patients With Liver Metastases From Colon Cancer
- Recruiting Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies
- Recruiting Perfusion CT as a Predictor of Treatment Response in Patients With Rectal Cancer
- Not Recruiting SonoVue®-Enhanced Ultrasound (US) Versus Unenhanced US for Focal Liver Lesion Characterization
Publications
- Dual-therapeutic reporter genes fusion for enhanced cancer gene therapy and imaging. Gene Ther. 2013; (5): 529-37
- Earlier detection of breast cancer with ultrasound molecular imaging in a transgenic mouse model. Cancer Res. 2013; (6): 1689-98
- Molecular Imaging of Inflammation in Inflammatory Bowel Disease with a Clinically Translatable Dual-Selectin-targeted US Contrast Agent: Comparison with FDG PET/CT in a Mouse Model. Radiology. 2013
- Adenocarcinoma of the uncinate process of the pancreas: MDCT patterns of local invasion and clinical features at presentation. Eur Radiol. 2012; (5): 1067-74
- Antiangiogenic and radiation therapy: early effects on in vivo computed tomography perfusion parameters in human colon cancer xenografts in mice. Invest Radiol. 2012; (1): 25-32
- Cationic versus neutral microbubbles for ultrasound-mediated gene delivery in cancer. Radiology. 2012; (3): 721-32
Help
Trial Administration